GlaxoSmithKline (LON:GSK)‘s stock had its “buy” rating restated by equities researchers at UBS Group in a research report issued to clients and investors on Friday, investing.thisismoney.co.uk reports.
GSK has been the topic of several other reports. Credit Suisse Group set a GBX 1,450 ($18.95) target price on GlaxoSmithKline and gave the company a “neutral” rating in a research report on Monday, July 16th. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of GlaxoSmithKline in a research report on Tuesday, October 23rd. Deutsche Bank reaffirmed a “hold” rating and set a GBX 1,525 ($19.93) target price on shares of GlaxoSmithKline in a research report on Thursday, September 6th. Kepler Capital Markets set a GBX 1,440 ($18.82) target price on GlaxoSmithKline and gave the company a “neutral” rating in a research report on Monday, July 30th. Finally, Cfra set a GBX 1,550 ($20.25) price target on GlaxoSmithKline and gave the company a “neutral” rating in a research note on Thursday, July 26th. One equities research analyst has rated the stock with a sell rating, eleven have issued a hold rating and nine have given a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of GBX 1,516.51 ($19.82).
Shares of LON:GSK opened at GBX 1,509.40 ($19.72) on Friday. GlaxoSmithKline has a 1 year low of GBX 1,235.20 ($16.14) and a 1 year high of GBX 1,724.50 ($22.53).
GlaxoSmithKline Company Profile
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.
Featured Article: Investing in Growth Stocks
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.